| abstract |
The present invention provides methods for treating Pneumocystis carinii pneumonia and Giardia lamblia in a subject in need of such treatment. The methods comprises administering to the subject a compound of Formula I: <IMAGE> (I) wherein: X and Y are located in the para or meta positions and are selected from the group consisting of H, loweralkyl, loweralkoxy, and <IMAGE> wherein: each R1 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl or two R1 groups together represent C2-C10 alkyl, hydroxyalkyl, or alkylene, or two R1 groups together represent <IMAGE> wherein m is from 1-3 and R7 is H or -CONHCR8NR9R10, wherein R8 is loweralkyl, and R9 and R10 are each independently selected from the group consisting of H and lower alkyl; R2 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl; n is a number from 0 to 2; R3 and R4 are each independently selected from the group consisting of H, loweralkyl, loweralkoxy, alkylaryl, aryl, oxyaryl, aminoalkyl, aminoaryl, or halogen; and R5 and R6 are each independently selected from the group consisting of H, loweralkyl, aryl, alkylaryl, aminoalkyl, aminoaryl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl; or a phamaceutically acceptable salt thereof. The compound of Formula I is administered in an amount effective to treat the condition. The present invention also provides compounds useful for the treatment of Pneumocystis carinii pneumonia and Giardia lamblia. |